Ten years after introducing one of the dairy world's more ambitious health-trait breeding tools, Geno's research and development team has quietly delivered a significant upgrade, and the timing says a lot about where dairy genetics is heading.
Geno has recalculated the statistical model behind its claw health index, the breeding value used to predict how resistant an animal's offsprings are likely to be to hoof and claw disorders.
The result is a meaningfully more accurate index, one that gives dairy farmers around the world more confidence in the numbers behind Geno's Norwegian Red bulls, and a firmer foundation for selecting the next generation.
A Decade in the Making
Geno launched the claw health index roughly ten years ago, built on recordings of three categories of disorder: corkscrew claw (a structural hoof deformity), infectious claw disorders (including digital dermatitis), and laminitis-related claw disorders (inflammation tied to nutrition and metabolic stress).
Since then, the data available to Geno has grown far richer. Recordings have multiplied many times over, and more of them now come from professional hoof trimmers rather than farmers themselves, producing more consistent diagnoses. With more animals contributing claw-health records over a longer period, the genetic evaluation is supported by a larger and more comprehensive dataset, helping improve the reliability of the estimated breeding values. That gave Geno's team the raw material to recalculate breeding values with a precision that was not possible a decade ago.
The Headline Number: Heritability Triples
The clearest sign of progress is in heritability — the share of variation in a trait attributable to genetics rather than environment or management. Across all three claw health traits, Geno's new model pushes this up sharply:
|
Trait |
Heritability (previous model) |
Heritability (new model) |
|
Corkscrew claw |
6% |
20% |
|
Infectious claw disorders |
3% |
8% |
|
Laminitis-related claw disorders |
2% |
6% |
Roughly a threefold increase across the board. In practice, that means an individual animal's own health records now carry substantially more weight in shaping its breeding value, rather than that value resting so heavily on distant relatives. Geno is also seeing stronger genetic correlations between several claw health traits, evidence that good genetics for one disorder tend to travel with good genetics for another.
The exception is the link between corkscrew claw and infectious claw disorders, which remains only moderate, suggesting these two conditions are still shaped by different underlying biology.
Clearer Daylight Between Bulls
At Geno's young bull testing station in Øyer, Norway, the new model produces roughly 20% greater spread in claw health index values among candidate bulls. Put simply: the genetic differences between bulls are now easier to tell apart, and a single point of difference carries more real biological weight than before. That feeds into modest but real shifts in each bull's overall Total Merit Index, claw health will now drive a larger share of genetic progress, not because Geno has changed what it is breeding for, but because it can now measure that goal more precisely.
Why This Matters Beyond Norway
Lameness and claw disease rank among the most expensive, welfare-sensitive issues in dairy production anywhere in the world, which is why this update matters beyond Geno's own breeding program:
Lameness is a top-tier cost driver globally. Research across the US, UK, and EU consistently places claw and hoof disorders alongside mastitis and fertility problems as the costliest categories of dairy cow health issue.
Low heritability has long been the industry-wide bottleneck. Claw disorders are heavily shaped by housing, flooring, nutrition, and trimming routines, making the genetic signal hard to isolate everywhere, not just in Norway. Geno's jump from 2–6% to 6–20% shows the ceiling on these traits is higher than older data suggested.
Better data discipline drove this, not new lab technology, a distinction worth noting for breeding organizations elsewhere, from CDCB in the US to AHDB in the UK to Interbull internationally.
Farmers using Norwegian Red genetics outside Norway benefit directly. Norwegian Red genetics are used in crossbreeding programs worldwide, notably in New Zealand, Ireland, the US, and UK, often prized specifically for fertility and health advantages. It reflects a broader shift toward welfare traits industry-wide — claw health, fertility, and longevity, as better data makes these traits genetically tractable and consumer and regulatory pressure pushes the industry in that direction.
Geno will continue revisiting its own tools as its data grows — this update is one step in that ongoing process, not a one-time fix.
